Potent Protective Immune Responses to Senecavirus Induced by Virus-Like Particle Vaccine in Pigs

文献类型： 外文期刊

第一作者： Mu, Suyu

作者： Mu, Suyu;Sun, Shiqi;Dong, Hu;Bai, Manyuan;Zhang, Yun;Teng, Zhidong;Ren, Mei;Yin, Shuanghui;Guo, Huichen;Guo, Huichen

作者机构：

关键词： Senecavirus A; vaccine; virus-like particles; animal infection model

期刊名称：VACCINES （ 影响因子：4.422； 五年影响因子：5.513 ）

ISSN：

年卷期： 2020 年 8 卷 3 期

页码：

收录情况： SCI

摘要： Senecavirus A (SVA) is the pathogen that has recently caused porcine idiopathic vesicular disease (PIVD). The clinical symptoms of PIVD are similar to those of acute foot-and-mouth disease and also can result in the death of newborn piglets, thus entailing economic losses. Vaccine immunization is the most effective way to prevent and control SVA. Among all SVA vaccines reported, only the SVA inactivated vaccine has been successfully developed. However, to ensure the elimination of this pathogen, safer and more effective vaccines are urgently required. A virus-like particles (VLPs)-based vaccine is probably the best alternative to inactivated vaccine. To develop an SVA VLPs vaccine and evaluate its immune effect, a prokaryotic expression system was used to produce SVA capsid protein and assemble VLPs. The VLPs were characterized by affinity chromatography, sucrose density gradient centrifugation, ZetaSizer and transmission electron microscopy. Meanwhile, the SVA CH-HB-2017 strain was used to infect pigs and to determine infection routes and dose. Experimental pigs were then immunized with the SVA VLPs vaccine emulsified in an ISA 201 adjuvant. The results showed that the VLPs vaccine induced neutralizing and specific antibodies at similar levels as an inactivated SVA vaccine after immunization. The level of INF-gamma induced by the VLPs vaccine gradually decreased-similar to that of inactivated vaccine. These results indicated that VLPs vaccine may simultaneously cause both cellular and humoral immune responses. Importantly, after the challenge, the VLPs vaccine provided similar levels of protection as the inactivated SVA vaccine. In this study, we successfully obtained novel SVA VLPs and confirmed their highly immunogenicity, thus providing a superior candidate vaccine for defense and elimination of SVA, compared to the inactivated vaccine.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序